期刊文献+

抗人呼吸道合胞病毒融合糖蛋白单克隆抗体的制备及体外鉴定 被引量:2

Primary Studies of Monoclonal Antibody Against Fusion Glycoprotein of Human Respiratory Syncytial Virus
原文传递
导出
摘要 目的:获得能稳定分泌抗人呼吸道合胞病毒(human respiratory syncytial virus,RSV)融合糖蛋白(fusion glycoprotein,F)单克隆抗体(monoclonal antibody,mAb)的杂交瘤细胞株,以期用于RSV感染的早期诊断和被动免疫治疗研究。方法:通过杂交瘤技术制备可特异性识别RSV F的单抗,体外鉴定生物学特性。结果:获得了可分泌抗RSV F蛋白的杂交瘤细胞株F8,体外连续传代培养2个月,能稳定分泌抗体F8,培养上清效价为1∶1000,亲和常数(Ka)为6.8×108L/mol。F8属IgG1型抗体,可特异性识别RSV F1亚单位的AA 205-222。免疫酶法蚀斑减少中和实验证实F8具有体外中和活性及融合抑制活性。结论:获得具有中和活性的抗RSV F蛋白的单克隆抗体,为RSV感染的早期诊断及被动免疫治疗等奠定了基础。 Objective: To obtain the hybridoma cell line stably secreting monoclonal antibody (mAb) specific for F glycoprotein (F) of human respiratory syncytial virus (RSV) for the further study of early detection and passive immunotherapy against RSV infection. Methods: The mAbs against F were prepared by hybridoma technology and then the associated characteristics were identified in vitro. Results : The hybridoma cell line of F8 capable of stably secreting mAb was established. It grew well after continuous culture for two months, the resultant supernatant titer of the mAb is 1 : 1000. The mAb is IgG1 and its relative affinity (Ka) is 6.8 ~ 108 L/tool. The potential epitope recognized by F8 is located around AA 205-222 of F1 subunit of RSV F. Through the immunoenzyme method, the neutralizing activity and fusion inhibition capacity of mAb F8 in vitro were also confirmed. Conclusion: The mAb F8 against RSV F with neutralizing activity was obtained. It lays a foundation for early diagnosis and passive immunotherapy of RSV infection.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2012年第2期63-68,共6页 China Biotechnology
基金 北京市自然科学基金资助项目(7092053)
关键词 人呼吸道合胞病毒 融合糖蛋白 单克隆抗体 杂交瘤技术 Human respiratory syncytial virus Fusion glycoprotein Monoclonal antibody Hybridomatechnology
  • 相关文献

参考文献12

  • 1陈慧中.流行性喘憋性肺炎的研究进展[J].临床儿科杂志,2005,23(9):602-604. 被引量:5
  • 2邓洁,钱渊,朱汝南,王芳,赵林清.2000年冬-2006年春北京地区急性呼吸道感染患儿中呼吸道合胞病毒的监测[J].中华儿科杂志,2006,44(12):924-927. 被引量:102
  • 3Wu H,Pfarr D S,Johnson S.Development of motavizumab,anultra-potent antibody for the prevention of respiratory syncytialvirus infection in the upper and lower respiratory tract.J MolBiol,2001,368(3):652-665.
  • 4Chambers P,Prugle C R,Easton A J.Sequence analysis of thegene encoding the fusion glycoprotein of pneumonia virus of micesuggests possible conserved secondary structure elements inparamyxovirus fusion glycoproteins.J Gen Virol,1992,73(Pt7):1717-1724.
  • 5Beatty J D,Beatty B G,Vlahos W G.Measurement of monoclonalantibody affinity by non-competitive enzyme immunoassay.Journalof Immunological Methods,1987,100(1-2):173-179.
  • 6王小波,何金生,付远辉,郑娴娴,方璇.呼吸道合胞病毒感染滴度测定方法的建立与比较[J].中华实验和临床病毒学杂志,2010,24(2):147-149. 被引量:1
  • 7Greenough A,Thomas M.Respiratory syncytial virus prevention:past and presents trategies.Expert Opin Pharmacther,2000,1(6):1195-1201.
  • 8Delgado M F.Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytialvirus disease.Nature Medicine,2008,15(1):34-41.
  • 9万文徽.单克隆抗体亲和常数的测定[J].单克隆抗体通讯,1993,9(2):72-75. 被引量:44
  • 10Collins P L,Crowe J E.Respiratory syncytial virus and metapneumovirus.In:Knipe D M,Howley PM,Griffin D E,et a1.Fields Virology.5th ed.Philadelphia:Lippincott Williams&Wilkins,2007.1601-1646.

二级参考文献30

  • 1刘成贵,王之梁,耿学辉,钱渊,杜金林,林良明,刘玉琳,张梓荆,王芳,张淑芳,李玲,赵玉娟,刘佳健,米杰.流行性喘憋性肺炎病原与合胞病毒抗原亚型的研究[J].中华儿科杂志,1994,32(1):22-23. 被引量:11
  • 2邓洁,朱汝南,钱渊,赵林清,王芳.北京地区2000—2004年分离的呼吸道合胞病毒B亚型株G蛋白基因的序列分析[J].中华微生物学和免疫学杂志,2006,26(1):1-5. 被引量:5
  • 3耿学辉,王之梁,钱渊,朱汝南,邓洁,杜金林,朱宗涵.呼吸道合胞病毒北京地区分离株G蛋白的基因分析[J].病毒学报,1996,12(4):317-322. 被引量:10
  • 4林良明 刘玉琳 等.1991年河北及天津部分地区儿童流行性喘憋性肺炎调查[J].中国妇幼保健,1993,8:51-53.
  • 5张梓荆.病毒性肺炎的现状与对策[J].中华儿科杂志,1997,35(8):397-397.
  • 6Kristensen K,Stensballe LG,Bjerre J,et al.Risk factors for respiratory syncytial virus hospitalization in children with heart disease.Arch Dis Child.2009,94:785-789.
  • 7Culley FJ,Pollott J,Openshaw PJ.Age at First Viral Infection Determines the Pattern of T cell-mediated Disease during Reinfection in Adulthood.J Exp Med.2002,196:1381-1386.
  • 8Hu A,Colella M,Tam JS,et al.Simultaneous Detection,Subgrouping,and Quantitation of respiratory Syncytial Virus A and B by Real-Time PCR.J Clin Microbiol.2003,41:149-154.
  • 9张梓荆 申昆玲 见:胡亚美 江载芳主编.流行性喘憋性肺炎[A].见:胡亚美,江载芳主编.诸福棠实用儿科学 .第 7版[C].北京:人民卫生出版社,2002.1201-1203.
  • 10张梓荆.流行性喘憋性肺炎[A].见:张梓荆主编.小儿病毒性呼吸道感染与病毒性肺炎[C].北京 :中国医药科技出版社,1990.249-257.

共引文献148

同被引文献85

  • 1Wu Y, Jin Y, Li Y, et al. NIR spectroscopy as a process analytical technology (PAT) tool for on-line and real-time monitoring of an extraction process[J]. Vib Spectrosc,2012,5 8 :109-118.
  • 2Xu B,Wu Z S,Lin Z Z,et al. NIR analysis for batch process of ethanol precipitation coupled with a new calibration model updating strategy[J]. Anal ChimActa, 2012, 720 ( 30 ) :2-28.
  • 3Dai J, Wang G, Li W, et al. High-throughput screening for anti-influenza A virus drugs and study of the mechanism of procyanidin on influenza A virus-induced autophagy[J]JBiomolScreen, 2012, 17(5): 605-617.
  • 4Liu C,Wang L,Xu Z,et al. A multilayer microdevice for cell-based high- throughput drug screening[J]. J Micromech Microeng, 2012,22 (6): 065008.
  • 5Li D,Wang M,Yang C,et al. Solid state characterizations and analysis of stability in azelnidipine polymorphs[J]. Chem Pharm Bull,2012,60( 8): 995-1002.
  • 6Yuan Y Z, Zhang M, Fan X L,et al. Impurity profiling of etimicin sulfate by liquid chromatography ion-trap mass spectrometry[J]. J Pharm B iomed Anal,2012,70:212-223.
  • 7Wang X, Zhou H, Zheng J, et al. Identification and character zation of four process-related impurities in retigabine[J]. J Pharm Biomed Anal, 2012,71:148-151.
  • 8Liu C H,Lu D D,Deng X X,et al.The analysis of major impurities of lipophilic-conjugated phosphorothioate oligonucleotides by ion- pair reversed-phase HPLC combined with MALDI-TOF-MS[J]. Anal Bioanal Chem,2012,403(5): 1333-1342.
  • 9Wang B L,Wang H,Wang E,et al.lsolation and structure characterizationof related impurities in Sodium Tanshinone IIA Sulfonate by LC/ESI- MSn and NMR[J] d Pharm B iomed Anal,2012,67/68:36-41.
  • 10Gao T, Liu Y X,Ji Y B,et al. Structural elucidation of impurities in 5-n-butyl-4- {4-[2-( 1H-tetrazole-5-yl)- 1H-pyrrol- 1 -yl]phenylmethyl } - 2,4-dihydro-2-(2,6-dichlorophenyl)-3H-l,2,4-triazol-3-one (Ib), a novel nonpeptide a ngiotensin AT receptor antagonist[J]. J Pharm Biomed Anal, 2012,66:81-386.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部